- 作者：Giuseppe Derosa<sup>asup><sup> ; sup><sup>bsup><sup> ; sup><sup>giuseppe.derosa@unipv.it" class="auth_mail" title="E-mail the corresponding authorsup> ; Angela D'Angelo<sup>asup> ; Pamela Maffioli<sup>asup><sup> ; sup><sup>csup>
- 关键词：Berberis aristata ; Insulin consumption ; Silybum marianum ; Type 1 diabetes mellitus
- 刊名：Clinical Nutrition
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：35
- 期：5
- 页码：1091-1095
- 全文大小：404 K
sSec_2">Material and methods
spara0015">85 type 1 diabetic patients were enrolled and randomized to take placebo or B. aristata/S. marianum 588/105 mg, 1 tablet at lunch and 1 tablet at dinner, for six months. We evaluated if there was a reduction of insulin dose necessary to reach an adequate glycemic control. We also evaluated at the study start, and after 6 months: body mass index (BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-prandial glucose (PPG), lipid profile.
sSec_3">Results
spara0020">We observed a reduction of total insulin consumption in B. aristata/S. marianum, both compared to baseline and to placebo. Regarding insulin administration at meals, we recorded that the group treated with B. aristata/S. marianum used less insulin at meals, and at bedtime. Glycated hemoglobin decreased with B. aristata/S. marianum compared to baseline, but not compared to placebo. There was a decrease of FPG, and PPG with B. aristata/S. marianum both compared to baseline and to placebo. Regarding lipid profile, we recorded a decrease of total cholesterol, triglycerides, and LDL-cholesterol and an increase of HDL-cholesterol with B. aristata/S. marianum, both compared to baseline and to placebo.
sSec_4">Conclusions
spara0025">The addition of B. aristata/S. marianum to insulin therapy in patients with type 1 diabetes mellitus leads to a reduction of the insulin dose necessary to have an adequate glycemic control.